Does the media refer more to ZBIO or LGND?

In the previous week, Ligand Pharmaceuticals had 9 more articles in the media than Zenas BioPharma. MarketBeat recorded 15 mentions for Ligand Pharmaceuticals and 6 mentions for Zenas BioPharma. Ligand Pharmaceuticals' average media sentiment score of 0.81 beat Zenas BioPharma's score of 0.68 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is ZBIO or CLDX more profitable?

Celldex Therapeutics' return on equity of -50.72% beat Zenas BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Zenas BioPharma N/A -99.99% -58.06% Celldex Therapeutics N/A -50.72% -46.59%

Does the media refer more to ZBIO or CLDX?

In the previous week, Zenas BioPharma had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 6 mentions for Zenas BioPharma and 4 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.62 beat Zenas BioPharma's score of 0.68 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to ZBIO or BCRX?

In the previous week, BioCryst Pharmaceuticals had 3 more articles in the media than Zenas BioPharma. MarketBeat recorded 9 mentions for BioCryst Pharmaceuticals and 6 mentions for Zenas BioPharma. BioCryst Pharmaceuticals' average media sentiment score of 1.06 beat Zenas BioPharma's score of 0.68 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor INVA or ZBIO?

In the previous week, Zenas BioPharma had 3 more articles in the media than Innoviva. MarketBeat recorded 6 mentions for Zenas BioPharma and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.37 beat Zenas BioPharma's score of 0.68 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ZBIO or NVAX?

In the previous week, Novavax had 10 more articles in the media than Zenas BioPharma. MarketBeat recorded 16 mentions for Novavax and 6 mentions for Zenas BioPharma. Novavax's average media sentiment score of 0.88 beat Zenas BioPharma's score of 0.68 indicating that Novavax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Zenas BioPharma (ZBIO) Competitors

$28.56 -0.23 (-0.78%)

As of 02:27 PM Eastern

Compare

ZBIO vs. LGND, CLDX, BCRX, INVA, and NVAX

Should you buy Zenas BioPharma stock or one of its competitors? MarketBeat compares Zenas BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zenas BioPharma include Ligand Pharmaceuticals (LGND), Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Innoviva (INVA), and Novavax (NVAX). These companies are all part of the "biotechnology" industry.

How does Zenas BioPharma compare to Ligand Pharmaceuticals?

Zenas BioPharma (NASDAQ:ZBIO) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

Zenas BioPharma presently has a consensus price target of $44.29, suggesting a potential upside of 55.09%. Ligand Pharmaceuticals has a consensus price target of $304.00, suggesting a potential upside of 2.64%. Given Zenas BioPharma's higher possible upside, equities analysts plainly believe Zenas BioPharma is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, Ligand Pharmaceuticals had 9 more articles in the media than Zenas BioPharma. MarketBeat recorded 15 mentions for Ligand Pharmaceuticals and 6 mentions for Zenas BioPharma. Ligand Pharmaceuticals' average media sentiment score of 0.81 beat Zenas BioPharma's score of 0.68 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Ligand Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	N/A	N/A	-$377.74M	-$8.47	N/A
Ligand Pharmaceuticals	$268.09M	22.14	$124.45M	$7.37	40.19

Zenas BioPharma has a beta of -0.96, suggesting that its stock price is 196% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

Ligand Pharmaceuticals has a net margin of 55.95% compared to Zenas BioPharma's net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 16.19% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

Summary

Ligand Pharmaceuticals beats Zenas BioPharma on 13 of the 15 factors compared between the two stocks.

How does Zenas BioPharma compare to Celldex Therapeutics?

Zenas BioPharma (NASDAQ:ZBIO) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Zenas BioPharma presently has a consensus target price of $44.29, suggesting a potential upside of 55.09%. Celldex Therapeutics has a consensus target price of $49.30, suggesting a potential upside of 27.72%. Given Zenas BioPharma's higher possible upside, analysts plainly believe Zenas BioPharma is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Celldex Therapeutics' return on equity of -50.72% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Celldex Therapeutics	N/A	-50.72%	-46.59%

Celldex Therapeutics has higher revenue and earnings than Zenas BioPharma. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	N/A	N/A	-$377.74M	-$8.47	N/A
Celldex Therapeutics	$1.54M	1,967.30	-$258.76M	-$4.26	N/A

Zenas BioPharma has a beta of -0.96, meaning that its stock price is 196% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

In the previous week, Zenas BioPharma had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 6 mentions for Zenas BioPharma and 4 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.62 beat Zenas BioPharma's score of 0.68 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Celldex Therapeutics beats Zenas BioPharma on 10 of the 13 factors compared between the two stocks.

How does Zenas BioPharma compare to BioCryst Pharmaceuticals?

Zenas BioPharma (NASDAQ:ZBIO) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Zenas BioPharma has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -51.71%. BioCryst Pharmaceuticals' return on equity of -76.36% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Zenas BioPharma presently has a consensus price target of $44.29, suggesting a potential upside of 55.09%. BioCryst Pharmaceuticals has a consensus price target of $20.80, suggesting a potential upside of 119.29%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, BioCryst Pharmaceuticals had 3 more articles in the media than Zenas BioPharma. MarketBeat recorded 9 mentions for BioCryst Pharmaceuticals and 6 mentions for Zenas BioPharma. BioCryst Pharmaceuticals' average media sentiment score of 1.06 beat Zenas BioPharma's score of 0.68 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zenas BioPharma has a beta of -0.96, suggesting that its share price is 196% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

BioCryst Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	N/A	N/A	-$377.74M	-$8.47	N/A
BioCryst Pharmaceuticals	$874.84M	2.76	$263.86M	-$1.78	N/A

Summary

BioCryst Pharmaceuticals beats Zenas BioPharma on 12 of the 15 factors compared between the two stocks.

How does Zenas BioPharma compare to Innoviva?

Innoviva (NASDAQ:INVA) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Innoviva has a net margin of 119.89% compared to Zenas BioPharma's net margin of 0.00%. Innoviva's return on equity of 33.33% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Zenas BioPharma	N/A	-99.99%	-58.06%

99.1% of Innoviva shares are owned by institutional investors. 2.0% of Innoviva shares are owned by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Innoviva has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.96, meaning that its stock price is 196% less volatile than the broader market.

In the previous week, Zenas BioPharma had 3 more articles in the media than Innoviva. MarketBeat recorded 6 mentions for Zenas BioPharma and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.37 beat Zenas BioPharma's score of 0.68 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.93	$271.17M	$6.01	3.64
Zenas BioPharma	N/A	N/A	-$377.74M	-$8.47	N/A

Innoviva currently has a consensus target price of $36.20, suggesting a potential upside of 65.45%. Zenas BioPharma has a consensus target price of $44.29, suggesting a potential upside of 55.09%. Given Innoviva's stronger consensus rating and higher probable upside, analysts plainly believe Innoviva is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Summary

Innoviva beats Zenas BioPharma on 12 of the 15 factors compared between the two stocks.

How does Zenas BioPharma compare to Novavax?

Zenas BioPharma (NASDAQ:ZBIO) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Zenas BioPharma presently has a consensus price target of $44.29, suggesting a potential upside of 55.09%. Novavax has a consensus price target of $13.00, suggesting a potential upside of 54.67%. Given Zenas BioPharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Zenas BioPharma is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40

Zenas BioPharma has a beta of -0.96, meaning that its share price is 196% less volatile than the broader market. Comparatively, Novavax has a beta of 2.43, meaning that its share price is 143% more volatile than the broader market.

Novavax has higher revenue and earnings than Zenas BioPharma. Novavax is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	N/A	N/A	-$377.74M	-$8.47	N/A
Novavax	$1.12B	1.23	$440.30M	-$0.58	N/A

Zenas BioPharma has a net margin of 0.00% compared to Novavax's net margin of -14.73%. Novavax's return on equity of -14.82% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Novavax	-14.73%	-14.82%	1.23%

53.0% of Novavax shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by company insiders. Comparatively, 1.6% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Novavax had 10 more articles in the media than Zenas BioPharma. MarketBeat recorded 16 mentions for Novavax and 6 mentions for Zenas BioPharma. Novavax's average media sentiment score of 0.88 beat Zenas BioPharma's score of 0.68 indicating that Novavax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Novavax beats Zenas BioPharma on 10 of the 16 factors compared between the two stocks.

Get Zenas BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZBIO vs. The Competition

Export

Metric	Zenas BioPharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.80B	$3.67B	$6.78B	$12.65B
Dividend Yield	N/A	2.19%	2.68%	8.43%
P/E Ratio	-3.37	21.48	27.13	24.40
Price / Sales	N/A	327.86	525.28	91.46
Price / Cash	N/A	143.66	48.59	59.39
Price / Book	6.33	8.55	10.85	6.33
Net Income	-$377.74M	$23.88M	$3.59B	$331.45M
7 Day Performance	-0.71%	-2.84%	-1.34%	0.18%
1 Month Performance	52.62%	5.93%	2.96%	-0.72%
1 Year Performance	131.21%	52.58%	28.93%	20.53%

Zenas BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZBIO Zenas BioPharma	3.5162 of 5 stars	$28.56 -0.8%	$44.29 +55.1%	+124.5%	$1.80B	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	2.8877 of 5 stars	$319.43 -0.3%	$257.71 -19.3%	+137.1%	$6.42B	$268.09M	43.34	80	News Coverage Analyst Forecast
CLDX Celldex Therapeutics	2.712 of 5 stars	$39.93 +5.2%	$49.30 +23.5%	+63.4%	$2.98B	$1.54M	N/A	150	Analyst Upgrade
BCRX BioCryst Pharmaceuticals	3.1883 of 5 stars	$10.99 +8.1%	$21.78 +98.2%	+8.7%	$2.58B	$885.72M	N/A	530	Positive News Analyst Forecast
INVA Innoviva	3.7526 of 5 stars	$22.25 +2.0%	$36.20 +62.7%	+11.0%	$1.61B	$411.33M	3.70	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZBIO) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zenas BioPharma (ZBIO) Competitors

ZBIO vs. LGND, CLDX, BCRX, INVA, and NVAX

How does Zenas BioPharma compare to Ligand Pharmaceuticals?

Summary

How does Zenas BioPharma compare to Celldex Therapeutics?

Summary

How does Zenas BioPharma compare to BioCryst Pharmaceuticals?

Summary

How does Zenas BioPharma compare to Innoviva?

Summary

How does Zenas BioPharma compare to Novavax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBIO vs. The Competition

Zenas BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zenas BioPharma (ZBIO) Competitors

ZBIO vs. LGND, CLDX, BCRX, INVA, and NVAX

How does Zenas BioPharma compare to Ligand Pharmaceuticals?

Do analysts recommend ZBIO or LGND?

Does the media refer more to ZBIO or LGND?

Do institutionals & insiders have more ownership in ZBIO or LGND?

Which has higher earnings and valuation, ZBIO or LGND?

Which has more risk and volatility, ZBIO or LGND?

Is ZBIO or LGND more profitable?

Summary

How does Zenas BioPharma compare to Celldex Therapeutics?

Do analysts prefer ZBIO or CLDX?

Is ZBIO or CLDX more profitable?

Which has higher earnings and valuation, ZBIO or CLDX?

Which has more risk & volatility, ZBIO or CLDX?

Does the media refer more to ZBIO or CLDX?

Summary

How does Zenas BioPharma compare to BioCryst Pharmaceuticals?

Is ZBIO or BCRX more profitable?

Do insiders and institutionals hold more shares of ZBIO or BCRX?

Do analysts recommend ZBIO or BCRX?

Does the media refer more to ZBIO or BCRX?

Which has more risk and volatility, ZBIO or BCRX?

Which has higher earnings & valuation, ZBIO or BCRX?

Summary

How does Zenas BioPharma compare to Innoviva?

Is INVA or ZBIO more profitable?

Do insiders & institutionals hold more shares of INVA or ZBIO?

Which has more volatility & risk, INVA or ZBIO?

Does the media favor INVA or ZBIO?

Which has preferable valuation and earnings, INVA or ZBIO?

Do analysts rate INVA or ZBIO?

Summary

How does Zenas BioPharma compare to Novavax?

Do analysts rate ZBIO or NVAX?

Which has more volatility and risk, ZBIO or NVAX?

Which has stronger earnings & valuation, ZBIO or NVAX?

Is ZBIO or NVAX more profitable?

Do institutionals and insiders hold more shares of ZBIO or NVAX?

Does the media favor ZBIO or NVAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBIO vs. The Competition

Zenas BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools